Full content PDFs

Debranding – the unacceptable face of pharma?
The industry as a whole likes to make much of its commitment to healthcare and at times lays claim to what approaches altruism. If such claims are to be believed, pharma needs to back off when it comes to exploiting regulatory loopholes such as the debranding scandal. As with tax avoidance, obeying the letter but not the spirit of the law does not best serve the interests of society as a whole.
Rob Munro 

Highlights from the Latest Advances in Psychiatry meeting
The 16th Latest Advances in Psychiatry Symposium took place in March at the Royal College of Physicians, presenting current perspectives on obsessive-compulsive disorder, adherence to oral antipsychotics and recognising body dysmorphic disorder.
Felix David 

Recognition and management of acute kidney injury
(click here for full web article)

Acute kidney injury (AKI) is associated with high morbidity and mortality, and early recognition is important. This article discusses the management of AKI in primary care with a focus on medicines optimisation, and describes when referral is necessary.
Thomas Oates and Shabbir Moochhala

Individualising treatment and care of patients with diabetes
Individualising the treatment and care of patients with diabetes was a key theme at the 2016 Diabetes Professional Care conference held in London last November. Susan Mayor reports on how to assess individual patients’ characteristics to set appropriate targets and how to make treatment decisions based on these targets.
Susan Mayor

New roles for clinical pharmacists in general practice
In 2015, NHS England launched its scheme to fund, recruit and employ more clinical pharmacists in GP practices. Since then, pharmacists have been playing an increasingly essential role in general practice, not only by reducing the workload of GPs but by bringing additional skills and knowledge on medicines optimisation, particularly in cases of complex polypharmacy.
Eleanor Barnes, Imran Ashraf and Aysha Din

Summary of the National Diabetes Audit 2015–16 report
The most recent National Diabetes Audit report on care processes and treatment targets shows that some progress is being made in NHS diabetes care, but there is still a large variation across England and Wales.
Steve Chaplin 

Biosimilars: ensuring safety in the search for savings
(click here for full web article) 
Biosimilars – cheaper versions of biopharmaceuticals produced by competing companies – have the potential to reduce the NHS drugs bill substantially. However, unlike generic drugs, biosimilars are not interchangeable with the original brand, raising safety concerns. Hence pharmacovigilance and prescribing by brand is essential.
Mark Greener

ADA position statement on diabetic neuropathy
The American Diabetes Association (ADA)’s recent position statement provides a useful summary of the current evidence on the prevention and management of diabetic neuropathy.
Steve Chaplin 

QALYs and their role in the NICE decision-making process
In the third article in our series on NICE guidance, we discuss Quality-Adjusted Life Years (QALYs), a key calculation used by NICE when assessing the cost-effectiveness of new treatments.
Joy Ogden

Can drug price hikes via debranding be prevented?
(click here for full web article)
Steep price hikes following the debranding of off-patent medicines are becoming increasingly common in the UK, adding hundreds of millions to the NHS drugs bill. But can anything be done to prevent this?
Farasat Bokhari and Bruce Lyons

Qtern: DPP-4 and SGLT2 inhibitor combination for type 2 diabetes
Qtern is a new fixeddose combination of the DPP-4 inhibitor saxagliptin with the SGLT2 inhibitor dapagliflozin for the control of type 2 diabetes. This article discusses its indications, place in therapy and clinical trial efficacy.
Steve Chaplin

PPIs and hypomagnesaemia: more common than we thought?
Proton pump inhibitors (PPIs) are associated with several well-documented side-effects but one emerging adverse effect, hypomagnesaemia, has so far tended to slip under the radar. In a small audit, the author investigated the rates of magnesium supplementation among PPI users, as a potential indicator of hypomagnesaemia. The results suggest this side-effect could be more common than previously thought.
Angus Thompson

Add yours ↓
Web design and marketing agency Leamington Spa